Alexion Pharmaceuticals, Inc.
Alexion’s Soliris eculizumab Receives Marketing Approval in Australia for All Patients with PNH
Published in Blood Weekly, March 12th, 2009
Alexion Pharmaceuticals, Inc., (Nasdaq:ALXN) announced that the Australian Government’s Therapeutic Goods Administration has approved the use of Soliris® (eculizumab) for the treatment of all patients in Australia with paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris is the first therapy approved in Australia for the treatment of PNH.
“Prior to this positive action by the government, there has not been an approved, safe and effective therapy for the treatment of patients with PNH in Australia,” said Professor Jeffrey Szer, M.B., B.S., FRACP, Director...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2009-03-12)
More Articles from Blood Weekly
- Harvard School of Public Health
Diets that reduce calories lead to weight loss, regardless of carbohydrate, protein or fat content - Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Reports Fourth Quarter and 2008 Financial Results - Biopsy
Research from A.M. Alkhunaizi et al broadens understanding of biopsy - Coagulation
Scientists at University of Amsterdam describe research in coagulation - Enzyme Research
Reports on enzyme research findings from Yale University, Medical Department provide new insights - Gastroenterology
Findings in gastroenterology reported from National Chung-Hsing University - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
